GLPwatch
Papers (9189)
Page 149 of 154, ranked by citation count.
- Use of liraglutide in type 1 diabetes: implications for management.
- Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study.
- Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.
- Comparing the performance of electrostatic repulsion-reversed phase chromatography approaches in the resolution of complex peptide mixture: Liraglutide as case study.
- [Changes in weight, body composition, metabolic parameters and vitamin D in subjects with grade 3 and 4 obesity treated with liraglutide 3 mg].
- European Society of Cardiology 2018.
- Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.
- No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.
- Size-exclusion LC-UV/HRMS based method for the analysis of aggregates in synthetic GLP-1 analog liraglutide and evaluation of excipient impact on aggregation.
- Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.
- Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
- Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.
- Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.
- GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.
- Assessment of cardiovascular event reduction with SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes mellitus.
- In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
- Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.
- Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice.
- Antihyperglycemic medications for cardiovascular disease risk reduction.
- Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.
- Impact of Exendin-4 on the Differentiation and Function of Transplanted Porcine Neonatal Pancreatic Cell Clusters in Diabetic Nude Mice.
- Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies.
- Short-term effects of liraglutide and semaglutide on weight gain and adiposity by rats fed a Western diet.
- Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea.
- Generalizability of glucagon-like peptide 1 receptor agonist clinical trial results to product labeling and the real world.
- Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.
- [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
- [Glucagon-like peptide-1: a cardiological perspective].
- [New outcome studies with injectable semaglutide in different at risk populations].
- The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
- Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.
- Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.
- [Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances].
- Improving sensitivity and drug tolerance of assays for neutralizing anti-drug antibodies to semaglutide and native GLP-1.
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
- London buses: A cardiovascular outcome trial equivalent?
- Medications for Obstructive Sleep Apnea.
- Longacting exenatide in diabetes: DURATION-3.
- Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics.
- Dual-phase exenatide delivery system: PLGA nanoparticles embedded in thermosensitive PLGA-PEG-PLGA hydrogel for sustained glycemic control.
- GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.
- Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.
- Is liraglutide the solution for weight loss in women with polycystic ovarian syndrome?
- Disparities in Adolescent and Young Adult Obesity Medication Dispensing: A Retrospective Linked EHR-Pharmacy Cohort, 2020-2025.
- Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity.
- Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
- Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management.
- Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.
- [The Preliminary Investigation of GLP-1 Receptor Agonist on Liver Steatosis in Obese Mice].
- Liraglutide in diabetes mellitus: More facts and findings.
- Glucagonlike peptide 1 analogs in diabetes care.
- liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
- Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"
- Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs).
- Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
- Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women.
- Oral Delivery of Liraglutide Formulated with PLGA for Sustained Obesity Management.
- Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.
- Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome.
- Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.